CClinicalTrials.gg
CompletedNCT03567603Updated Jul 20, 2023

Sound Processing Changes in Babies With Opioid Exposure

An observational study in Neonatal Abstinence Syndrome, sponsored by University of Rochester. Completed at 1 site in United States. Open to participants aged Up to 20 Days. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by University of Rochester · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
37
Ages
Up to 20 Days
Sex
All
01

Study summary

The purpose of this study is to identify problems with interpreting sounds in babies that have been exposed to opioids prior to birth. Being able to identify these issues in infancy may allow us to find children who may have problems with language learning later in life so that we can try to minimize these.

Read the detailed description

This is a single center prospective study of neonates >36 weeks' gestation prenatally exposed to psychoactive substances and gestationally age-matched controls. Evoked response potentials on EEG in response to auditory oddball paradigms will be compared between cohorts. Analyses will try to identify differences in auditory processing using ANOVAs to compare the mismatch negativity measures, amplitudes and latencies as a function of study group.

02

Conditions studied

  • Neonatal Abstinence Syndrome
03

In context

Neonatal Abstinence Syndrome

65 studies on the registry are indexed under Neonatal Abstinence Syndrome; 6 are open to participants now.

This study's enrollment of 37 is below the median of 50 across 15 observational studies indexed under Neonatal Abstinence Syndrome.

Browse Neonatal Abstinence Syndrome studies →

Lead sponsor

University of Rochester is the lead sponsor of 715 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 20 Days
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Investigators with routine access to infant and maternal records will identify subjects based on review of patient charts upon admission to the NICU or nursery.

Inclusion criteria

  • Gestational age ≥ 36 weeks, confirmation of dates via ultrasound or last menstrual period
  • Prenatal opioid exposure ("exposed"), confirmed via admitted use or newborn drug screen; no prenatal opioid exposure ("control") by maternal report or testing
  • All races, ethnicities, sexes to be included
  • Informed permission form signed by mother

Exclusion criteria

Exclusion Criteria:

  • Birth weight ≤ 3rd percentile or ≥ 97th percentile for gestational age
  • Have comorbid medical disorders including; those associated with sensorineural hearing loss, significant congenital anomalies, congenital heart disease, known brain injury/malformations
  • Infants requiring mechanical ventilation
  • Infants requiring continuous sedation
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
37 participants (actual)
Patient registry
No

Groups and cohorts

  • opioid exposed neonates

    prenatal opioid exposure

  • non-opioid exposed neonates

    no prenatal opioid exposure

06

What researchers measure

Primary outcomes

  1. Percent with neonates with auditory cortical processing deficiencies

    A bone conducting sound playback lead will be placed over a bony prominence on the skull to transmit the auditory oddball paradigm that will be repeatedly played via this lead. The oddball paradigm will consist of a repeating sound loop including multiple identical 5-30 decibels tones of same duration interspersed with single 5-30 decibels tone of different pitch but same duration (deviant tone). Continuous EEG recordings will be collected during playback. EEG tracings will be analyzed specifically for the mismatch negativity waveforms. Comparisons will be made between the deviant and standard responses (sound tones) and the percentage of neonates with no difference between the standard and deviant waveforms will be determined.

    Time frame: baseline

07

Study locations

1 site
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03567603
Lead sponsor
University of Rochester
Responsible party
Ronnie Guillet (Professor of Pediatrics, University of Rochester) — Principal investigator
First posted
Jun 26, 2018
Start date
Mar 25, 2019
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Jul 20, 2023

Study contacts

Ronnie Guillet, MD, PHD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion